On November 20, Shenzhen Salus BioMed Technology Co., Ltd. signed a pivotal agreement to establish a state-of-the-art multi-omics equipment and reagent development project in Changzhou. The ceremony was attended by key city leaders, including Hang Yong, Standing Committee Member and Secretary General of the CPC Changzhou Municipal Committee, and Deputy Mayor Pan Dongling.
As a recognized “Little Giant” in technology innovation, Salus BioMed excels in synthetic biology and gene sequencing. The company is at the forefront of developing high-throughput gene sequencers and is working on a globally leading ultra-resolution spatial omics platform. This project introduces advanced solutions for genomic research, including low, medium, and high-throughput gene sequencers and a next-generation spatial omics research tool. The tools utilize cutting-edge technologies such as ultra-high-density chips, micro-fluorescent labeling, and ultra-fast chemical reactions to set new benchmarks for speed, accuracy, and cost-efficiency in sequencing.
The facility, to be located in Changzhou West Taihu Lake Science and Technology Industrial Zone, will prioritize the research, development, and industrialization of genomic and spatial multi-omics technologies. Salus BioMed's innovations are expected to empower hospitals, clinical labs, and pharmaceutical companies with high-performance, accessible sequencing solutions, significantly reducing costs and expanding capabilities.
This partnership aligns with Changzhou’s strategic goals of fostering innovation in advanced healthcare technologies and strengthening its medical and synthetic biology industries. The project will bolster supply chains, enhance regional competitiveness, and contribute to the city’s transformation into a leading hub for high-tech industries.
扫一扫在手机打开当前页  |
